RxDoctor Payments Data

Nishit Choksi, MD

Cardiovascular Disease · Dearborn, MINPI 1992764641

Payments from drug & device makers

$128,425in general payments, 2019–2025

Across 868 payments — averaging $147.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$63K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$13K
  • Cardiovascular Systems Inc.$11K
  • Novartis$9K
  • Edwards Lifesciences$6K
  • Vifor (international) Ltd.$5K
  • plus $22K from 54 others

What the payments were for

  • Consulting fees$3,7509%
  • Speaking & faculty fees$10,99527%
  • Travel & lodging$4,00510%
  • Food & beverage$21,89053%
  • Education$3291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
CSL Behring39$63,307
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)23$12,709
Cardiovascular Systems Inc.30$11,103
Novartis68$8,615
Edwards Lifesciences30$6,400
Vifor (international) Ltd.1$4,500
Abbott58$3,528
Endologix LLC150$3,141
Shockwave Medical, Inc5$1,992
Johnson & Johnson56$1,066
Bard Peripheral Vascular, Inc.6$1,058
AstraZeneca46$828
Medtronic(2 entities)14$813
Merck43$811
Inari Medical, Inc.15$785
E.r. Squibb & Sons, L.L.C.58$776
Heartflow, Inc.9$667
Boston Scientific19$598
Kestra Medical Technology Services, Inc.19$459
Boehringer Ingelheim17$386
Actelion Pharmaceuticals US, Inc.9$353
Kiniksa Pharmaceuticals, Ltd.14$342
Astellas Pharma US Inc5$331
Pfizer17$302
Amgen14$283
Terumo Medical Corporation2$265
Impulse Dynamics (USA) Inc.2$244
Stryker6$243
Alnylam Pharmaceuticals Inc.13$240
Biotronik Inc.3$222
Abiomed7$211
Scpharmaceuticals Inc.7$159
Lexicon Pharmaceuticals, Inc.7$133
Cvrx, Inc.1$123
Cordis US CORP.6$109
Cagent Vascular Inc1$103
Novo Nordisk4$102
Ablative Solutions, Inc.1$102
United Therapeutics Corporation4$101
Bayer4$99
Chiesi USA, Inc.4$92
Kiniksa Pharmaceuticals International, PLC2$70
Cardiva Medical, Inc.3$70
Philips North America LLC1$61
Angiodynamics, Inc.2$56
Penumbra, Inc.3$50
Asahi Intecc USA, Inc.1$41
Bridgebio Pharma, Inc.1$34
Imperative Care, Inc1$32
Lilly USA, LLC2$32
Reflow Medical Inc1$32
Cardinal Health 200 LLC1$31
Esperion Therapeutics, Inc.2$30
Medicomp Inc1$28
Irhythm Technologies, Inc.1$25
Amarin Pharma, Inc.2$25
Tactile Systems Technology Inc1$19
Azurity Pharmaceuticals, Inc.1$19
Baxter Healthcare1$18
Sanofi-aventis U.S. LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$128,425 in reported general payments places this provider in the 90th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$642,548
Medicare patients
1,062
Services billed
5,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban522$628,308
EntrestoSacubitril/Valsartan385$472,586
XareltoRivaroxaban107$143,352
JardianceEmpagliflozin94$113,739
Repatha SureclickEvolocumab95$88,488
VerquvoVericiguat80$85,308
FarxigaDapagliflozin Propanediol66$68,542
BrilintaTicagrelor77$63,498
Praluent PenAlirocumab23$21,781
Repatha SyringeEvolocumab28$20,296
ClopidogrelClopidogrel Bisulfate1,043$19,553
Metoprolol Succinate884$15,696
Ranolazine ErRanolazine134$14,343
Atorvastatin Calcium986$12,415
Midodrine Hcl71$6,561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$302$628,308522 claims
NovartisEntresto$8,615$472,586385 claims
Johnson & JohnsonXarelto$1,066$143,352107 claims
AstraZenecaFarxiga, Brilinta$828$132,040143 claims
Boehringer IngelheimJardiance$386$113,73994 claims
MerckVerquvo$811$85,30880 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →